Devalingam Mahalingam

  • 2824 Citations
  • 28 h-Index
20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    Correction to: Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation (CardioVascular and Interventional Radiology, (2019), 42, 5, (700-711), 10.1007/s00270-019-02191-z)

    Ali, R., Yang, Y., Antkowiak, M., Gabr, A., Mora, R., Abouchaleh, N., Asadi, A. A., Kulik, L., Ganger, D., Abecassis, M., Katariya, N., Mulcahy, M., Benson, A., Mahalingam, D., Thornburg, B., Mouli, S., Lewandowski, R. J., Salem, R. & Riaz, A., May 1 2020, In : Cardiovascular and Interventional Radiology. 43, 5, p. 806 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase Ib study a C

    Mahalingam, D., Wilkinson, G. A., Eng, K. H., Fields, P., Raber, P., Moseley, J. L., Cheetham, K., Coffey, M., Nuovo, G., Kalinski, P., Zhang, B., Arora, S. P. & Fountzilas, C., Jan 1 2020, In : Clinical Cancer Research. 26, 1, p. 71-81 11 p.

    Research output: Contribution to journalArticle

    Open Access
  • 7 Scopus citations

    Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

    Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Sep 1 2020, In : British Journal of Clinical Pharmacology. 86, 9, p. 1836-1848 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma

    O'Reilly, E. M., Barone, D., Mahalingam, D., Bekaii-Saab, T., Shao, S. H., Wolf, J., Rosano, M., Krause, S., Richards, D. A., Yu, K. H., Roach, J. M., Flaherty, K. T. & Ryan, D. P., Jun 2020, In : European Journal of Cancer. 132, p. 112-121 10 p.

    Research output: Contribution to journalArticle

  • The landscape of targeted therapies in TNBC

    Vagia, E., Mahalingam, D. & Cristofanilli, M., Apr 2020, In : Cancers. 12, 4, 916.

    Research output: Contribution to journalReview article

    Open Access
  • 7 Scopus citations